Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience (LEXX) completed dosing on schedule in its human pilot study GLP-1-H26-7, which compares oral semaglutide formulations. The five-week study compares Lexaria's DehydraTECH-semaglutide tablet and capsule with Wegovy tablets, assessing safety, tolerability and how semaglutide levels in the blood change over time.
All participants completed their final visits, and final blood samples were collected. Laboratory analysis comes next. Study information will not be shared with third parties until all data have been reviewed and checked for quality. Existing corporate resources fully fund the study.
Lexaria Bioscience (NASDAQ:LEXX) has entered an agreement with an unnamed pharmaceutical company to evaluate DehydraTECH with proprietary molecules.
The partner, identified as PharmCo, will supply one or more molecules for processing with Lexaria's patented drug-delivery technology and evaluation. The agreement is separate from Lexaria's two existing Material Transfer Agreements with other pharmaceutical companies. Lexaria expects that successful evaluation could potentially lead toward a licensing agreement with economic terms. PharmCo requested that its identity and specific agreement details remain undisclosed. Lexaria plans an update after the initial studies, including any decisions on licensing or other business.
Lexaria Bioscience (Nasdaq: LEXX) reported four additional patent awards covering its DehydraTECH drug delivery technology, bringing its portfolio to 70 granted patents.
US Patent 12,691,163, granted July 28, 2026, covers DehydraTECH processes for GLP-1 molecules in a diabetes patent family. US Patent 12,758,566, granted October 13, covers DehydraTECH-processed cannabidiol (CBD) for treating diabetes. Canadian Patent 3,199,547, granted October 20, covers processed CBD for treating hypertension. European Patent 4522159 was published with an October 21 grant date and covers processed CBD for treating epilepsy.
Lexaria expects its research programs to support intellectual property creation, commercial relationships and revenue growth from licensing its technology.
Lexaria Bioscience (NASDAQ:LEXX) has fully enrolled its human pilot study comparing oral DehydraTECH-semaglutide formulations with Wegovy tablets, with dosing continuing on schedule.
The five-week, three-arm study GLP-1-H26-7 evaluates safety, tolerability and drug levels in the body using tablet and capsule formulations. The final arm began dosing in early October; Lexaria expects that group to finish dosing in mid-November, followed by laboratory sample analyses and reporting. The company expects the dosing period to allow drug concentrations to reach a balance between intake and elimination. The study is fully funded from existing corporate resources.
Lexaria Bioscience (LEXX) reported animal study GLP-1-A26-1 results showing higher brain absorption for alternative DehydraTECH-CBD formulations than its historical reference formulation. Three CBD alternatives had higher mean brain concentrations eight hours after dosing; ALT2 showed a 566% improvement. CBD ALT1 also had higher mean blood absorption measures, but none of the CBD alternatives differed statistically significantly from the reference.
Semaglutide ALT2 performed best among its alternatives, although its mean blood absorption measures were below the reference and not statistically significantly different. Semaglutide brain concentrations were below the assay's quantitation limit. Lexaria has filed three new patent applications related to the tested formulations and is considering further applications of the findings.
Lexaria Bioscience (NASDAQ:LEXX) provided a strategic update on its ongoing evaluation of DehydraTECH for oral weight-loss and diabetes drugs. Lexaria and pharmaceutical industry partners are evaluating the technology for GLP-1 receptor agonists, a class of drugs used in these treatments.
Lexaria said its increasing focus on this sector began in 2023 and that it is working toward eventual adoption of DehydraTECH in the oral GLP-1 market.
Lexaria Bioscience (LEXX) reported an improved cash position after raising US$7.9 million from an Australian tax refund and institutional financing.
The institutional financing was priced at US$12.92 per share, and with 2.1 million shares outstanding, Lexaria reports about US$4.60 per share in current cash on hand. Management states that this fresh capital extends the company’s cash runway through 2027 and that there is no intention to pursue additional equity or debt financings in 2026. Lexaria also expects future business development relationships to fund a greater share of 2027 R&D costs and plans to provide updates on its 2026 and 2027 R&D programs.
Lexaria Bioscience (LEXX) has closed the previously announced cash exercise of certain outstanding warrants for an aggregate 453,969 common shares at a reduced exercise price of $12.92 per share, generating approximately $5.9 million in gross proceeds before fees.
In connection with the exercise, Lexaria issued new unregistered Series A and Series B warrants, each series covering up to 453,969 shares at an exercise price of $12.67 per share. The Series A warrants are immediately exercisable and expire five years after the effective date of a planned resale registration statement, while the Series B warrants are immediately exercisable and expire eighteen months after that effective date. Lexaria expects to use the net proceeds for working capital and general corporate purposes.
Lexaria Bioscience (LEXX) entered definitive agreements for the immediate cash exercise of 453,969 outstanding warrants at a reduced exercise price of $12.92 per share. Closing is expected on or about September 9, 2026, subject to customary conditions.
The warrant exercises are expected to generate approximately $5.9 million in gross proceeds before fees, to be used for working capital and general corporate purposes. In exchange, Lexaria will issue new unregistered Series A and Series B warrants for up to 453,969 shares each, both exercisable immediately at $12.67 per share, with five‑year and eighteen‑month terms, respectively, from the effective date of a planned resale registration statement. The CEO also cites a recently received $2.6 million Australian tax rebate as additional funding for 2027 operations and R&D.
Lexaria Bioscience (LEXX) will participate in the 28th Annual H.C. Wainwright Global Investment Conference in New York City from September 14–16, 2026. CEO Richard Christopher will deliver a company presentation and hold one-on-one investor meetings, with the presentation also accessible online via a provided link.